Clinical trials: Optic Neuritis
- Condition Optic Neuritis
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Multiple Sclerosis, Acute Optic Neuritis
Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
The primary objective of the study is to characterize the pharmacokinetics (PK) of BIIB033-B and to compare the PK profile with that of BIIB033-A in healthy volunteers.
- Trial name
- NCT02833142
- Testing
- BIIB033 (opicinumab)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis, NMO Spectrum Disorder
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome
- Trial name
- RECLAIM (NCT06280755)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- icometrix
Optic Neuritis, Optic; Neuritis, With Demyelination
BN201 SAD MAD Study in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of BN201 in healthy subjects.
- Trial name
- NCT03630497
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Accure Therapeutics
Multiple Sclerosis, NMO Spectrum Disorder
A Study of LP-168 in Healthy Volunteers
This is a Phase I study designed to assess the safety, tolerability and pharmacokinetics of LP-168 in healthy human volunteers.
- Trial name
- NCT05432713
- Testing
- LP-168 tablet
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.